Hims & Hers Health (NYSE:HIMS) Given “Buy” Rating at Seaport Res Ptn

Seaport Res Ptn reaffirmed their buy rating on shares of Hims & Hers Health (NYSE:HIMS) in a research report released on Friday, Zacks.com reports.

Other analysts have also recently issued reports about the company. Imperial Capital raised Hims & Hers Health from an in-line rating to an outperform rating and set a $16.00 price target for the company in a report on Wednesday, February 28th. Piper Sandler boosted their target price on shares of Hims & Hers Health from $9.00 to $11.00 and gave the stock a neutral rating in a research report on Tuesday, February 27th. Canaccord Genuity Group started coverage on shares of Hims & Hers Health in a report on Wednesday, April 10th. They issued a buy rating and a $20.00 price target for the company. Jefferies Financial Group reissued a hold rating and set a $15.00 price objective (down previously from $17.00) on shares of Hims & Hers Health in a report on Tuesday, April 16th. Finally, Citigroup upped their target price on shares of Hims & Hers Health from $12.00 to $16.00 and gave the stock a buy rating in a research report on Tuesday, February 27th. Five equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and an average price target of $14.85.

Hims & Hers Health Trading Up 0.4 %

NYSE:HIMS opened at $12.55 on Friday. The stock’s 50 day simple moving average is $13.80 and its 200-day simple moving average is $10.14. Hims & Hers Health has a 12-month low of $5.65 and a 12-month high of $17.16. The firm has a market cap of $2.69 billion, a P/E ratio of -114.05 and a beta of 0.91.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, February 26th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.03. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The company had revenue of $246.60 million for the quarter, compared to analysts’ expectations of $245.84 million. During the same period in the previous year, the company posted ($0.05) EPS. Hims & Hers Health’s revenue was up 47.4% compared to the same quarter last year. Research analysts forecast that Hims & Hers Health will post 0.1 EPS for the current fiscal year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $14.97, for a total value of $2,827,653.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, insider Soleil Boughton sold 2,503 shares of Hims & Hers Health stock in a transaction on Monday, April 15th. The stock was sold at an average price of $13.95, for a total value of $34,916.85. Following the completion of the sale, the insider now owns 164,363 shares of the company’s stock, valued at $2,292,863.85. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $14.97, for a total value of $2,827,653.36. The disclosure for this sale can be found here. Insiders have sold a total of 533,050 shares of company stock valued at $7,191,666 over the last quarter. Insiders own 31.63% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

Several hedge funds have recently modified their holdings of HIMS. Belpointe Asset Management LLC lifted its stake in shares of Hims & Hers Health by 10.0% in the 4th quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock valued at $118,000 after purchasing an additional 1,205 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Hims & Hers Health by 5.6% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,335 shares of the company’s stock valued at $261,000 after buying an additional 1,561 shares in the last quarter. Pathstone Family Office LLC grew its stake in Hims & Hers Health by 2.8% during the third quarter. Pathstone Family Office LLC now owns 65,876 shares of the company’s stock worth $414,000 after buying an additional 1,824 shares during the period. Principal Financial Group Inc. increased its position in shares of Hims & Hers Health by 17.9% in the first quarter. Principal Financial Group Inc. now owns 16,655 shares of the company’s stock worth $258,000 after acquiring an additional 2,525 shares in the last quarter. Finally, Baldwin Brothers LLC MA raised its stake in shares of Hims & Hers Health by 17.0% in the 4th quarter. Baldwin Brothers LLC MA now owns 22,128 shares of the company’s stock valued at $197,000 after acquiring an additional 3,215 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.